BU08028
BU08028| 식별자 | |
|---|---|
| |
| CAS 번호 | |
| PubChem CID | |
| 켐스파이더 | |
| 화학 및 물리 데이터 | |
| 공식 | C30H43NO4 |
| 몰 질량 | 481.677 g/g−1/g |
| 3D 모델(JSmol) | |
| |
| |
BU08028은 μ-오피오이드 수용체와 노시셉틴 수용체 모두에서 강력한 부분작용제 역할을 하는 약물이다.그것은 측쇄에 탄소 1개만 연장된 부프레놀핀의 상동체이지만, 노키셉틴 수용체에서 상대적으로 더 큰 활성을 가지며,[1][2][3][4] 진통제를 손상시키지 않고 남용 가능성을 감소시키는 것으로 생각된다.
「 」를 참조해 주세요.
레퍼런스
- ^ Cami-Kobeci G, Polgar WE, Khroyan TV, Toll L, Husbands SM (October 2011). "Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine". Journal of Medicinal Chemistry. 54 (19): 6531–7. doi:10.1021/jm2003238. PMC 3188691. PMID 21866885.
- ^ Khroyan TV, Polgar WE, Cami-Kobeci G, Husbands SM, Zaveri NT, Toll L (March 2011). "The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward". The Journal of Pharmacology and Experimental Therapeutics. 336 (3): 952–61. doi:10.1124/jpet.110.175620. PMC 3061529. PMID 21177476.
- ^ Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, et al. (September 2016). "A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates". Proceedings of the National Academy of Sciences of the United States of America. 113 (37): E5511-8. doi:10.1073/pnas.1605295113. PMC 5027459. PMID 27573832.
- ^ Kiguchi N, Ding H, Ko MC (April 2020). "Therapeutic potentials of NOP and MOP receptor coactivation for the treatment of pain and opioid abuse". Journal of Neuroscience Research. doi:10.1002/jnr.24624. PMC 7573817. PMID 32255240.